Compare The Coca-Cola Co K (KO) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Nuvalent Inc — how do they compare? The Coca-Cola Co K trades at $82.03 (market cap $353.32B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: The Coca-Cola Co K is far larger — about 36× Nuvalent Inc's market cap, and The Coca-Cola Co K pays a 2.58% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| KO | NUVL | |
|---|---|---|
Market Cap | $353.32B | $9.81B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Technology |
52-Week High | $84.92 | $123.96 |
52-Week Low | $65.67 | $72.16 |
Enterprise Value | $383.39B | $8.52B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $82.08, up 0.64% on the day, with a bullish analyst consensus and strong earnings beats in recent quarters. The stock shows robust profitability with a 27.8% net margin and 45.8% ROE, though valuations like a P/E of 25.82 are elevated. Technicals are mixed with a bearish overall signal but support near $82. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.
Outlook remains positive given consistent dividend growth, earnings outperformance, and a $90.67 price target. Risks include high debt levels and regional demand volatility. The stock offers stability for income investors but faces valuation pressures amid macroeconomic uncertainty.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported a net loss of $425.38 million for 2025 and negative cash flow from operations. Recent news is dominated by GSK's proposed acquisition of Nuvalent for $124 per share, announced in June 2026, which is under investigation by multiple law firms for fairness to shareholders.
The investment outlook is heavily influenced by the pending acquisition. While analyst consensus shows no sell ratings, the stock price is near the offer price, limiting upside. Key risks include the deal's completion and the company's ongoing losses. The primary opportunity is the acquisition premium, but fundamental challenges persist absent the deal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
